InflaRx N.V. (NASDAQ:IFRX) Receives $6.17 Consensus PT from Brokerages

InflaRx N.V. (NASDAQ:IFRX) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $6.1667.

IFRX has been the topic of several research analyst reports. Guggenheim restated a “buy” rating and set a $14.00 target price on shares of InflaRx in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research note on Friday, March 27th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of InflaRx in a report on Tuesday, December 30th. Finally, Raymond James Financial restated an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st.

InflaRx Trading Down 2.5%

InflaRx stock opened at $1.56 on Tuesday. The firm has a market cap of $112.77 million, a price-to-earnings ratio of -2.05 and a beta of 1.49. The stock has a fifty day simple moving average of $1.01 and a two-hundred day simple moving average of $1.10. InflaRx has a 12 month low of $0.71 and a 12 month high of $1.94.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Friday, March 20th. The company reported ($0.17) earnings per share for the quarter, hitting the consensus estimate of ($0.17). The business had revenue of ($0.04) million during the quarter, compared to analysts’ expectations of $0.03 million. On average, equities research analysts forecast that InflaRx will post -0.6 EPS for the current fiscal year.

Hedge Funds Weigh In On InflaRx

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE purchased a new stake in InflaRx during the third quarter valued at $3,316,000. Suvretta Capital Management LLC boosted its position in InflaRx by 22.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock worth $8,013,000 after purchasing an additional 1,450,000 shares during the last quarter. 683 Capital Management LLC grew its stake in shares of InflaRx by 47.3% during the 4th quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after purchasing an additional 1,065,000 shares during the period. Woodline Partners LP purchased a new stake in shares of InflaRx during the 1st quarter valued at about $766,000. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in shares of InflaRx during the 2nd quarter valued at about $262,000. 42.39% of the stock is owned by institutional investors.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.